share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director George Simeon

SEC announcement ·  Feb 28 07:42
Summary by Futu AI
George Simeon, associated with CRISPR Therapeutics AG [CRSP], engaged in a significant acquisition of the company's common stock on February 27, 2024. The transaction, which is currently in progress, involved the purchase of a total of 1,048,951 shares at a uniform price of $71.50 per share. Following these transactions, Simeon's holdings in CRISPR Therapeutics amount to 769,196 shares. The nature of the indirect beneficial ownership is detailed in notes associated with the transaction records.
George Simeon, associated with CRISPR Therapeutics AG [CRSP], engaged in a significant acquisition of the company's common stock on February 27, 2024. The transaction, which is currently in progress, involved the purchase of a total of 1,048,951 shares at a uniform price of $71.50 per share. Following these transactions, Simeon's holdings in CRISPR Therapeutics amount to 769,196 shares. The nature of the indirect beneficial ownership is detailed in notes associated with the transaction records.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.